KRAS and non-small cell lung carcinoma: As such it would be very interesting to compare levels of ACOX2 in a larger cohort of patients with KRAS mutations against a similar number of NSCLC wild-type for KRAS to determine if there may be any functional or biological link to sensitivity to MEK inhibitors.